

About Servier

– Backgrounder –

Servier is France's leading independent pharmaceutical company and the country's second largest drug company. Servier is present in 140 countries worldwide. R&D at Servier spans a range of therapeutic fields, with the main areas of focus being cardiovascular disease, neuroscience, oncology, metabolic disorders, and rheumatology. In the field of cardiovascular disease in particular, Servier is one of the principal research organizations dedicated to the development of new medicines.

Cardiovascular commitment

Servier has a long-standing interest in the field of cardiovascular disease. Nearly two thirds (63%) of Servier's global turnover from medicines is made up of drugs targeted at cardiovascular diseases.

Servier is unique among global pharmaceutical companies in that all the company's cardiovascular products it has introduced have stemmed from its own research efforts.

Procoralan* (ivabradine) is the first and only specific and selective I_f current inhibitor of the sinus node. Procoralan was approved in 2005 by the European regulatory authorities (EMA) for clinical use in selected patients with chronic stable angina. It is currently available in around 70 countries worldwide.

Servier's cardiovascular portfolio also includes **Coversyl® (perindopril)**, Servier's leading product for high blood pressure, heart failure, and for the treatment of patients with stable coronary artery disease (CAD) to reduce the risk of coronary events, **Vastarel MR® (trimetazidine)** for stable angina and **Preterax® (perindopril / indapamide)** and **Natrilix® SR (indapamide)** for hypertension.

Servier and landmark clinical trials

Servier has been involved in several large-scale outcomes clinical trials for several years including the **BEAUTIFUL (MorBidity-mortality Evaluation of the I_f Inhibitor ivabradine in patients with coronary disease and left ventricular dysfunction)** trial, which demonstrated the benefits of Procoralan (ivabradine) in reducing cardiovascular events in patients with coronary artery disease (CAD) receiving current preventative therapy. The results of this trial have major implications for the management of cardiovascular disease.

Other Servier trials include the **ADVANCE** (Action in Diabetes and Vascular Disease: PreterAx and DiamicroN MR Controlled Evaluation) study. This is the world's largest prospective mortality/morbidity trial in patients with type 2 diabetes to date. The study demonstrated the effects of blood pressure lowering with Preterax®-based therapy¹ and intensive glucose-lowering with Diamicron MR-based therapy² on the risk of complications in patients with type 2 diabetes.¹

The efficacy of perindopril alone and in combination has been investigated in a number of trials. The **PROGRESS** (Perindopril prOtection aGainst REcurrent Stroke Study) showed that perindopril 4 mg ± indapamide 2.5 mg reduced the risk of stroke by 29% in patients with a history of cerebrovascular disease.³

The **EUROPA** study (European trial on Reduction Of cardiac events with Perindopril in stable coronary Artery disease) showed that perindopril 8 mg is associated with a 20% reduction in the risk of cardiovascular death, myocardial infarction, and cardiac arrest compared with placebo in patients with coronary heart disease.⁴

Other significant, independent, investigator-led trials include **ASCOT-BPLA**⁵ in hypertension (amlodipine ± perindopril), **PREAMI**⁶ in postmyocardial infarction in elderly (perindopril) and **PEP-CHF**⁷ in diastolic heart failure (perindopril).

** Depending on the country, ivabradine is available as Procoralan®, Coralan®, Coraxan®, or Corlentor®*

References

1. Patel A, MacMahon S, Chalmers J, et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. *Lancet*. 2007 ; 370 : 829-40.
2. ADVANCE collaborative group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med*. 2008 ; 358 : 2560-72.
3. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. *Lancet* 2001 ; 358 : 1033-41.
4. Fox KM. European trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). *Lancet*. 2003 ; 362 : 762-68.
5. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. *Lancet*. 2005 ; 366 : 895-906.

6. The PREAMI Investigators. Effects of angiotensin-converting enzyme inhibition with perindopril on left ventricular remodelling and clinical outcome. Results of the Randomized Perindopril and Remodeling in Elderly with Acute Myocardial Infarction (PREAMI) study. *Arch Intern Med.* 2006 ; 166 : 659-66.
7. PEP-CHF Investigators. The Perindopril in Elderly People with Chronic Heart Failure (PEP-CHF) study. *Eur Heart J.* 2006 ; 27 : 2338-2445.